Skip to content
Market concentration allows pharmacy benefit managers (PBMs) to siphon off funds from our health care system while increasing costs to patients and reducing access […]
House hearing delves into antitrust problems of PBMs Read More »
Voters want to bolster American manufacturing across biopharmaceutical and biotechnology sectors, according to a new public opinion survey conducted by Morning Consult for the
New survey checks pulse on voters’ concerns for innovation and biomanufacturing Read More »
“The world of biotechnology is in the midst of a wave of exciting research and clinical advances—from artificial intelligence-based drug discovery to cell and
GEN State of Biotechnology 2024: John F. Crowley on driving biotech forward Read More »
The announcement of “maximum fair prices” for the first 10 medicines targeted under the Inflation Reduction Act (IRA) has renewed questions and concerns about
The economics of the Inflation Reduction Act’s impact on innovation Read More »
Drug price controls in the Inflation Reduction Act (IRA) involve unconstitutional coercion and will destroy innovation in transformational treatments that save patients’ lives, the
BIO files amicus brief challenging IRA drug price controls Read More »
In recent years, the number of disruptive, cutting-edge therapies approved or under review by the Food and Drug Administration (FDA) has grown substantially. So-called
Innovative payment arrangements bring transformative therapies from the lab to patients Read More »
The Inflation Reduction Act (IRA) has already begun to shift the way that innovative companies are investing in future breakthroughs. Over the past few
Farm workers considered to be at highest risk of infection with avian flu would receive seasonal influenza vaccinations for fall flu season under a new program
CDC plans seasonal flu vaccine campaign among farm workers at risk of H5N1 Read More »
Members of the public shared emotional stories about how practices by pharmacy benefit managers (PBMs) increase the cost of drugs, reduce patient access, and
Emotional testimonies expose harmful impact of PBMs at FTC hearing Read More »
The Federal Trade Commission will host an open meeting this morning, and fortunately, drug middlemen are on the agenda. The meeting will review the findings
FTC to air grievances with PBMs’ abusive practices Read More »
